Novavax Nuvaxovid COVID-19 vaccine receives expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovidï¾™ (COVID-19 Vaccine (Recombinant…
U.S. pandemic death toll higher than in 20 peer countries
On Nov. 18, 2022, the Journal of the American Medical Association reported that the U.S. experienced high COVID-19…
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint of superiority against omicron variants
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
University of Missouri study found Monkeypox mutations caused virus to spread rapidly, evade drugs and vaccines
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
NIH-funded study showed blood pressure levels rose during pandemic
On Nov. 1, 2022, the National Institutes of Health (NIH) announced that adults with hypertension saw a small,…
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
Reported cancer deaths continued downward trend; modest improvements in survival for pancreatic cancer
On Oct. 27, 2022, the National Institutes of Health announced that overall cancer death rates continued to decline…
University of Washington reported global COVID cases will increase in coming months, but at a slower pace
On Oct. 25, 2022, the University of Washington reported that daily global COVID-19 infections were projected to rise…
COVID-causing virus in air detected with high-tech bubbles
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, the U.S. FDA recommended the use of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) as…
EMA’s CHMP for Human Use issued positive opinion recommending authorization for use of Spikevax in children 6 months – 5 years in EU
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
90-Day analysis showed Moderna’s Omicron BA.1-targeting bivalent vaccine, mRNA-1273.214, demonstrated superior antibody response as fourth booster Compared to Spikevax Prototype Booster
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
Pfizer and BioNTech received positive CHMP ppinion for COMIRNATYï¾® in children 6 months to less than 5 lears in EU
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyï¾’s (EMA) Committee for Medicinal Products…
Moderna announced supply agreement with Gavi that secured access to updated variant-specific COVID-19 vaccines for low-and-middle income countries
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders…
Novavax COVID-19-influenza combination vaccine candidate induced antibody and T-Cell responses against SARS-CoV-2 and influenza
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
Gene associated with better immune response and protection after COVID-19 vaccination identified by Oxford researchers
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Biotechnology | CDC | COVID-19 | FDA | Life Science News
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
Intranasal COVID-19 vaccine candidateï¾’s clinical data highlighted need for further development of nasal spray vaccines
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
Novavax and SK bioscience filed post approval change application in South Korea for Nuvaxovidï¾™ COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
Switzerland’s Federal Office of Public Health recommended Novavax Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that Switzerlands Federal Office of Public Health had recommended Nuvaxovidï¾™(NVX-CoV2373) as a…
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5…
Japanese vaccine database Created to assess Vaccine Effectiveness and adverse events
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…